# Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

> **NCT03583710** · PHASE3 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 240 (estimated)

## Conditions studied

- ENSAT Stage I Adrenal Cortex Carcinoma
- ENSAT Stage II Adrenal Cortex Carcinoma
- ENSAT Stage III Adrenal Cortex Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Mitotane
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03583710
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-20
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583710, "Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03583710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*